Stefan Hatzl

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/605831/publications.pdf

Version: 2024-02-01

28 624 12 papers citations h-index

29 29 29 1058 all docs docs citations times ranked citing authors

23

g-index

#	Article	IF	CITATIONS
1	Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients—a multinational observational study by the European Confederation of Medical Mycology. Clinical Microbiology and Infection, 2022, 28, 580-587.	6.0	133
2	Autopsy Proven Pulmonary Mucormycosis Due to Rhizopus microsporus in a Critically Ill COVID-19 Patient with Underlying Hematological Malignancy. Journal of Fungi (Basel, Switzerland), 2021, 7, 88.	3. 5	79
3	Antifungal prophylaxis for prevention of COVID-19-associated pulmonary aspergillosis in critically ill patients: an observational study. Critical Care, 2021, 25, 335.	5.8	61
4	Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs. International Journal of Molecular Sciences, 2016, 17, 2080.	4.1	58
5	Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia. Clinical Epigenetics, 2021, 13, 1.	4.1	57
6	Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP. Cancer Research, 2016, 76, 3644-3654.	0.9	45
7	CD19+IgD+CD27- NaÃve B Cells as Predictors of Humoral Response to COVID 19 mRNA Vaccination in Immunocompromised Patients. Frontiers in Immunology, 2021, 12, 803742.	4.8	27
8	NR4A3 Suppresses Lymphomagenesis through Induction of Proapoptotic Genes. Cancer Research, 2017, 77, 2375-2386.	0.9	24
9	Response to "COVID-19 in persons with haematological cancers― Leukemia, 2020, 34, 2265-2270.	7.2	19
10	Immunohistochemistry for câ€myc and bclâ€2 overexpression improves risk stratification in primary central nervous system lymphoma. Hematological Oncology, 2020, 38, 277-283.	1.7	19
11	Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation. Journal of Antimicrobial Chemotherapy, 2022, 77, 2500-2505.	3.0	17
12	Increased Expression of Micro-RNA-23a Mediates Chemoresistance to Cytarabine in Acute Myeloid Leukemia. Cancers, 2020, 12, 496.	3.7	12
13	Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis. Haematologica, 2020, 105, 375-386.	3.5	11
14	Convalescent plasma therapy and mortality in COVID-19 patients admitted to the ICU: a prospective observational study. Annals of Intensive Care, 2021, 11, 73.	4.6	9
15	Antibiotic use and ileocolonic immune cells in patients receiving fecal microbiota transplantation for refractory intestinal GvHD: a prospective cohort study. Therapeutic Advances in Hematology, 2021, 12, 204062072110583.	2.5	9
16	Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation. PLoS ONE, 2015, 10, e0129859.	2.5	8
17	Soluble urokinase plasminogen activator receptor (suPAR) predicts critical illness and kidney failure in patients admitted to the intensive care unit. Scientific Reports, 2021, 11, 17476.	3.3	8
18	Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel. Thrombosis and Haemostasis, 2022, 122, 633-645.	3.4	7

#	Article	lF	CITATIONS
19	Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathy. Supportive Care in Cancer, 2021, 29, 5197-5207.	2.2	6
20	Deletion of SPRY4 is a frequent event in secondary acute myeloid leukemia. Annals of Hematology, 2015, 94, 1923-1924.	1.8	5
21	The role of germline mutation profiling in the selection of related donors for haematopoietic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 1502-1505.	2.4	3
22	EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity. Leukemia, 2021, 35, 1521-1526.	7.2	3
23	The Role of Immunohistochemical Overexpression of p53 as Adverse Prognostic Factor in Primary Testicular Diffuse Large B Cell Lymphoma. Pathology and Oncology Research, 2020, 26, 2831-2833.	1.9	2
24	miR-23a mediates resistance to hypomethylating agents in myeloid neoplasms. Annals of Hematology, 2021, 100, 2845-2847.	1.8	1
25	Early Treatment with Sotrovimab for Covid-19. New England Journal of Medicine, 2022, , .	27.0	1
26	AÂwearable cardioverter defibrillator for prevention of sudden cardiac death in aÂhematologic patient—aÂcase report. Memo - Magazine of European Medical Oncology, 2019, 12, 269-271.	0.5	0
27	Heparins as cancer therapy: in theory, they should have worked. Lancet Haematology,the, 2020, 7, e703-e704.	4.6	0
28	Prognostic Value of Baseline and Interim Positron Emission Tomography Markers in Diffuse Large B-cell Lymphoma Patients: A Real-world Perspective. HemaSphere, 2021, 5, e621.	2.7	0